Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel
NASDAQ:ACRS

Aclaris Therapeutics Q1 2026 Earnings Report

Aclaris Therapeutics logo
$4.74 -0.01 (-0.23%)
As of 11:43 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Aclaris Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.16
Beat/Miss
N/A
One Year Ago EPS
N/A

Aclaris Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.24 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aclaris Therapeutics Announcement Details

Quarter
Q1 2026
Date
5/14/2026
Time
Before Market Opens
Conference Call Date
Thursday, May 14, 2026
Conference Call Time
12:30PM ET

Conference Call Resources

Aclaris Therapeutics Earnings Headlines

Guggenheim initiates coverage of Aclaris Therapeutics (ACRS) with buy recommendation
 |  msn.comhttps://www.msn.com/en-us/money/top-stocks/guggenheim-initiates-coverage-of-aclaris-therapeutics-acrs-with-buy-recommendation/ar-AA22umq0
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
May 4 at 12:39 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/companies-aclaris-therapeutics-nasdaq-acrs-100429354.html
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page.tc pixel
May 6 at 1:00 AM  |  Weiss Ratings (Ad)
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript
April 28, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4895275-aclaris-therapeutics-inc-acrs-discusses-clinical-program-update-and-progress-of-lead
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates - Slideshow
April 28, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4895277-aclaris-therapeutics-inc-acrs-discusses-clinical-program-update-and-progress-of-lead
Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti ...
April 28, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/aclaris-therapeutics-announces-positive-full-top-line-first-in-human-results-from-phase-1a-healthy-volunteer-clinical-trial-of-ati-052-a-novel-potential-first-in-class-anti-tslp-il-4r-bispecific-1036071212
See More Aclaris Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aclaris Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclaris Therapeutics and other key companies, straight to your email.

About Aclaris Therapeutics

Aclaris Therapeutics (NASDAQ:ACRS) (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates. The company’s development strategy emphasizes both topical and oral small molecules that aim to provide targeted modulation of immune pathways with favorable safety and tolerability profiles.

Aclaris’s clinical programs span Phase 2 and Phase 3 trials, supported by strategic interactions with regulatory authorities and collaborations with diagnostic and academic partners. While the company currently focuses on patient populations in the United States, it maintains a framework for future expansion into select international markets through licensing arrangements and strategic alliances.

The leadership team is headed by Chief Executive Officer Adam Gould, whose background includes extensive experience in dermatology drug development and regulatory affairs. Supported by a board of directors with deep expertise in pharmaceutical research, clinical operations and commercialization, Aclaris is positioned to advance its late‐stage pipeline toward potential approval and market launch.

View Aclaris Therapeutics Profile
Earnings Tools